Stereotactic body radiotherapy appears to be an effective treatment option for patients with organ-confined prostate cancer, according to two separate studies presented at the American Association for Radiation Oncology annual meeting in Boston.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.